Oncolytic virus therapy benefits from control theory
نویسندگان
چکیده
منابع مشابه
Sendai Virus-Based Oncolytic Gene Therapy
The first gene therapy that was used on humans was performed for adenosine deaminase (ADA) deficiency in 1990 [1]. In the early days of gene therapy, it was thought to be a break‐ through in the treatment of a number of human diseases including cancer, cardiovascular disease, genetic disease, and so on. However, two severe adverse events in gene therapy served as triggers for the rethinking of ...
متن کاملMindfulness from theory to therapy
Mindfulness-based cognitive therapy involves, components of Beck cognitive therapy and mindfulness-based stress reduction therapy provided by Kabat-Zinn and in a therapy group to work with persons with a history of depression and thus vulnerable period later developed.This training of people to broaden their perspective to see maladaptive thoughts, ruminations thought processes and cognitive im...
متن کاملOncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticle...
متن کاملComputational approaches to study oncolytic virus therapy: insights and challenges
The paper reviews computational models for analyzing the use of replicating oncolytic viruses as therapeutic agents against cancers. The paper highlights viral and host paramters which are crucial for success, and discusses how virus strains can be optimized in order to achieve maximial remission of cancers. The models consider three mechansisms by which oncolytic virus therapy could work: (i) ...
متن کاملChina approves world's first oncolytic virus therapy for cancer treatment.
Oncolytic virus research got a welcome boost last November when Chinese regulators approved the world’s fi rst oncolytic viral therapy for cancer, Shanghai Sunway Biotech’s genetically modifi ed adenovirus H101. “ It’s fantastic for the fi eld, ” said John Bell , Ph.D., of the Ottawa Health Research Institute in Canada. “ We needed to have something that was a success, and so I think this is a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Royal Society Open Science
سال: 2020
ISSN: 2054-5703
DOI: 10.1098/rsos.200473